<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355914</url>
  </required_header>
  <id_info>
    <org_study_id>protocol3</org_study_id>
    <nct_id>NCT00355914</nct_id>
  </id_info>
  <brief_title>Effectiveness of Lumbar Facet Joint Nerve Blocks</brief_title>
  <official_title>A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Facet Joint Nerve Blocks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pain Management Center of Paducah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pain Management Center of Paducah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To demonstrate whether:

           i. Facet joint nerve blocks have therapeutic value beyond the duration of local
           anesthetic effect.

           ii. Adjuvant medications (Sarapin and Depo-steroids) provide additional relief of lumbar
           facet joint pain when used with facet joint nerve blocks.

        2. To demonstrate whether or not there are clinically significant improvements in function
           of patients who receive lumbar facet joint nerve block with or without Sarapin and
           Depo-steroids (Group II) compared to patients randomized to Group I who receive only
           local anesthetic blocks.

        3. To determine the adverse event profile in both groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measure(s) To demonstrate a clinically significant difference between the
      patients treated with adjuvants and those patients randomized to Group I in the pain status,
      physical, and psychological status and pain at 3, 6, 12, 18and 24 months post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Numeric Rating Scale</measure>
    <time_frame>Baseline, 3, 6, 12, 18, and 24 months post-treatment</time_frame>
    <description>Numeric rating scale represented 0 with no pain and 10 with the worst pain imaginable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>Baseline, 3, 6, 12, 18, and 24 months post-treatment.</time_frame>
    <description>Oswestry Disability Index 2.0 (ODI): ODI score is ranged from 0 to 50. Total score is converted in to percent disability. ODI Scoring: 0% to 20% (minimal disability), 21%-40% (moderate disability), 41%-60% (severe disability), 61%-80% (crippled) and 81%-100% (may be bed bound or exaggerating their symptoms).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Group 1 Without Steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 With Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Facet Joint Nerve Block</intervention_name>
    <description>Lumbar Facet Joint Nerve Block</description>
    <arm_group_label>Group 1 Without Steroids</arm_group_label>
    <arm_group_label>Group 2 With Steroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive for facet joint pain with comparative local anesthetic blocks

        Candidates are over 18 years of age

        Subjects with a history of chronic, function limiting low back pain of at least six months
        in duration Subjects who are able to give voluntary, written informed consent to
        participate in this investigation Subjects who, in the opinion of the Investigator, are
        able to understand this investigation, co-operate with the investigational procedures and
        are willing to return to the center for all the required post-operative follow-ups The
        subject has not had recent surgical procedures within the last three months.

        Exclusion Criteria:

          -  Negative or false-positive response to controlled comparative local anesthetic blocks

        Narcotic use of greater than Hydrocodone 100 mg/day, Methadone 80 mg or Morphine 100 mg, or
        dose equivalent

        Uncontrolled major Depression or uncontrolled psychiatric disorders

        Uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency,
        chronic liver dysfunction, progressive neurological deficit, urinary sphincter dysfunction,
        infection, increased intercranial pressure, pseudotumor cerebri, intercranial tumors,
        unstable angina, and severe chronic obstructive pulmonary disease.

        Chronic severe conditions that could interfere with the interpretations of the outcome
        assessments for pain and bodily function

        Women who are pregnant or lactating

        Subjects who have participated in a clinical study with an investigational product within
        30 days of enrollment

        Patients with multiple complaints involving concomitant hip osteoarthritis, will not be
        amenable to study due to the overlap of pain complaints.

        Inability to achieve appropriate positioning and inability to understand informed consent
        and protocol History of adverse reaction to local anesthetic or anti-inflammatory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laxmaiah Manchikanti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ambulatory Surgery Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Surgery Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880841/pdf/ijmsv07p0124.pdf</url>
    <description>Evaluation of lumbar facet joint nerve blocks in managing chronic low back pain: a randomized, double-blind, controlled trial with a 2-year follow-up.</description>
  </link>
  <results_reference>
    <citation>Manchikanti L, Singh V, Falco FJ, Cash KA, Pampati V. Evaluation of lumbar facet joint nerve blocks in managing chronic low back pain: a randomized, double-blind, controlled trial with a 2-year follow-up. Int J Med Sci. 2010 May 28;7(3):124-35.</citation>
    <PMID>20567613</PMID>
  </results_reference>
  <results_reference>
    <citation>Manchikanti L, Singh V, Falco FJ, Cash KA, Pampati V. Lumbar facet joint nerve blocks in managing chronic facet joint pain: one-year follow-up of a randomized, double-blind controlled trial: Clinical Trial NCT00355914. Pain Physician. 2008 Mar-Apr;11(2):121-32.</citation>
    <PMID>18354721</PMID>
  </results_reference>
  <results_reference>
    <citation>Manchikanti L, Manchikanti KN, Manchukonda R, Cash KA, Damron KS, Pampati V, McManus CD. Evaluation of lumbar facet joint nerve blocks in the management of chronic low back pain: preliminary report of a randomized, double-blind controlled trial: clinical trial NCT00355914. Pain Physician. 2007 May;10(3):425-40.</citation>
    <PMID>17525777</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>September 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2013</results_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pain Management Center of Paducah</investigator_affiliation>
    <investigator_full_name>Laxmaiah Manchikanti, MD</investigator_full_name>
    <investigator_title>CEO</investigator_title>
  </responsible_party>
  <keyword>Lumbar Facet Joint Nerve Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period lasted from November 2003 to July 2006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Without Steroids</title>
          <description>Lumbar Facet Joint block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)</description>
        </group>
        <group group_id="P2">
          <title>Group II With Steroids</title>
          <description>Lumbar Facet Joint block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and Steroids (0.15 mg of non-particulate betamethasone)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Without Steroids</title>
          <description>Lumbar Facet Joint Nerve Blocks Local anesthetic without steroids</description>
        </group>
        <group group_id="B2">
          <title>Group II With Steroids</title>
          <description>Lumbar Facet Joint Nerve Blocks Local anesthetic with steroids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="15"/>
                    <measurement group_id="B2" value="46" spread="17"/>
                    <measurement group_id="B3" value="46.7" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Numeric Rating Scale</title>
        <description>Numeric rating scale represented 0 with no pain and 10 with the worst pain imaginable.</description>
        <time_frame>Baseline, 3, 6, 12, 18, and 24 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Local anesthetic without steroids</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Local anesthetic with steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Average Numeric Rating Scale</title>
          <description>Numeric rating scale represented 0 with no pain and 10 with the worst pain imaginable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="0.8"/>
                    <measurement group_id="O2" value="7.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.3"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.5"/>
                    <measurement group_id="O2" value="3.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.7"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                    <measurement group_id="O2" value="3.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                    <measurement group_id="O2" value="3.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>compared baseline, 3, 6, 12, 18, and 24 months between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Results were considered statistically significant if the P value was less than 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oswestry Disability Index</title>
        <description>Oswestry Disability Index 2.0 (ODI): ODI score is ranged from 0 to 50. Total score is converted in to percent disability. ODI Scoring: 0% to 20% (minimal disability), 21%-40% (moderate disability), 41%-60% (severe disability), 61%-80% (crippled) and 81%-100% (may be bed bound or exaggerating their symptoms).</description>
        <time_frame>Baseline, 3, 6, 12, 18, and 24 months post-treatment.</time_frame>
        <population>An intent-to-treat-analysis was performed on all patients utilizing the last follow-up data. Initial data were utilized in the patients who dropped out of the study without further follow-up after the first treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Without Steroids</title>
            <description>Lumbar Facet Joint Nerve Blocks Local anesthetic without steroids</description>
          </group>
          <group group_id="O2">
            <title>Group II With Steroids</title>
            <description>Facet Joint Nerve Blocks Local anesthetic with steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index</title>
          <description>Oswestry Disability Index 2.0 (ODI): ODI score is ranged from 0 to 50. Total score is converted in to percent disability. ODI Scoring: 0% to 20% (minimal disability), 21%-40% (moderate disability), 41%-60% (severe disability), 61%-80% (crippled) and 81%-100% (may be bed bound or exaggerating their symptoms).</description>
          <population>An intent-to-treat-analysis was performed on all patients utilizing the last follow-up data. Initial data were utilized in the patients who dropped out of the study without further follow-up after the first treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="4.6"/>
                    <measurement group_id="O2" value="25.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.7"/>
                    <measurement group_id="O2" value="13.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.7"/>
                    <measurement group_id="O2" value="12.2" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="4.8"/>
                    <measurement group_id="O2" value="12.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="5.0"/>
                    <measurement group_id="O2" value="11.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="4.9"/>
                    <measurement group_id="O2" value="11.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>baseline, 3, 6, 12, 18, and 24 months between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Results were considered statistically significant if the P value was less than 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Without Steroids</title>
          <description>Lumbar Facet Joint Nerve Blocks Local anesthetic without steroids</description>
        </group>
        <group group_id="E2">
          <title>Group II With Steroids</title>
          <description>Facet Joint Nerve Blocks Local anesthetic with steroids</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laxmaiah Manchikanti, MD</name_or_title>
      <organization>Pain Management Center of Paducah, Paducah, KY</organization>
      <phone>2705548373 ext 100</phone>
      <email>drlm@thepainmd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

